Trial and Study Updates
When new updates from ongoing trials and studies are made available, we'll try to provide them here.
Retatrutide: What the Latest Phase 3 Data Tells Us -- and What Happens Next
2026-10-07
For several years, retatrutide has carried one of the biggest reputations in obesity research. Now we finally have enough Phase 3 evidence to start separating the reputation from the data. And the data is substantial. Retatrutide, formerly known as LY3437943, is Eli Lilly's investigational once-weekly "triple agonist". The molecule activates three hormone receptors:- GLP-1- GIP- […]

